A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of Evolocumab (AMG145) on LDL-C in Subjects With Severe Familial Hypercholesterolemia.
Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 17 Jun 2017
At a glance
- Drugs Evolocumab (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Adverse reactions; Registrational
- Acronyms PROFICIO; TAUSSIG
- Sponsors Amgen
- 10 Jun 2017 Biomarkers information updated
- 08 Jun 2016 Last checked against United Kingdom Clinical Research Network.
- 22 Jan 2016 Results published in Amgen media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History